RGRX Statistics
Total Valuation
RegeneRx Biopharmaceuticals has a market cap or net worth of 2,112.
| Market Cap | 2,112 |
| Enterprise Value | n/a |
Important Dates
The next estimated earnings date is Friday, April 4, 2025.
| Earnings Date | Apr 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RegeneRx Biopharmaceuticals has 1.51 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 1.51M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.63% |
| Owned by Institutions (%) | n/a |
| Float | 847,872 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.03 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.07
| Current Ratio | 0.07 |
| Quick Ratio | 0.06 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.19 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -148.50% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 25,587 |
| Profits Per Employee | -562,863 |
| Employee Count | 3 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +16.67% in the last 52 weeks. The beta is 2.73, so RegeneRx Biopharmaceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 2.73 |
| 52-Week Price Change | +16.67% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 44.44 |
| Average Volume (20 Days) | 134 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, RegeneRx Biopharmaceuticals had revenue of 76,760 and -1.69 million in losses. Loss per share was -1.18.
| Revenue | 76,760 |
| Gross Profit | 76,760 |
| Operating Income | -1.36M |
| Pretax Income | -1.69M |
| Net Income | -1.69M |
| EBITDA | n/a |
| EBIT | -1.36M |
| Loss Per Share | -1.18 |
Balance Sheet
The company has 101,557 in cash and 1.49 million in debt, giving a net cash position of -1.39 million or -0.92 per share.
| Cash & Cash Equivalents | 101,557 |
| Total Debt | 1.49M |
| Net Cash | -1.39M |
| Net Cash Per Share | -0.92 |
| Equity (Book Value) | -3.74M |
| Book Value Per Share | -2.61 |
| Working Capital | -1.68M |
Cash Flow
| Operating Cash Flow | -823,747 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,775.75% |
| Pretax Margin | -2,199.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RegeneRx Biopharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.74% |
| Shareholder Yield | -1.74% |
| Earnings Yield | -79,952.18% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on October 18, 2023. It was a reverse split with a ratio of 0.01.
| Last Split Date | Oct 18, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.01 |
Scores
RegeneRx Biopharmaceuticals has an Altman Z-Score of -874.85. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -874.85 |
| Piotroski F-Score | n/a |